Cargando…

Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis

Background: The purpose of this work was to assess the activity of para-aminosalicylic acid (PAS) in combination with isoniazid (INH) against clinical isolates of Mycobacterium tuberculosis (MTB). Materials and methods: A total of 72 MTB isolates with differential in vitro drug susceptibilities were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Tingting, Jiang, Guanglu, Wen, Shu’an, Huo, Fengmin, Wang, Fen, Huang, Hairong, Pang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497846/ https://www.ncbi.nlm.nih.gov/pubmed/31114264 http://dx.doi.org/10.2147/IDR.S200697

Ejemplares similares

Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
por: Jing, Wei, et al.
Publicado: (2017)

Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis
por: Pandey, Bharati, et al.
Publicado: (2019)

Molecular characterization of para-aminosalicylic acid resistant Mycobacterium tuberculosis clinical isolates in southwestern China
por: Luo, Ming, et al.
Publicado: (2019)

Decreased Methylenetetrahydrofolate Reductase Activity Leads to Increased Sensitivity to para-Aminosalicylic Acid in Mycobacterium tuberculosis
por: Yu, Ji-fang, et al.
Publicado: (2022)

para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
por: Zheng, Jun, et al.
Publicado: (2013)

Para-Aminosalicylic Acid in Pulmonary Tuberculosis
por: Horne, Norman W.
Publicado: (1949)

dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains
por: Moradigaravand, Danesh, et al.
Publicado: (2016)

Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
por: Wang, Wei, et al.
Publicado: (2022)

A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis
por: Heo, Jinyeong, et al.
Publicado: (2022)

Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis
por: Zhang, Fuzhen, et al.
Publicado: (2020)

In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China
por: Yu, Xia, et al.
Publicado: (2021)

Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid
por: Jaiswal, Indu, et al.
Publicado: (2017)

Blood Agar Validation for Susceptibility Testing of Isoniazid, Rifampicin, Ethambutol, and Streptomycin to Mycobacterium tuberculosis Isolates
por: Coban, Ahmet Yilmaz
Publicado: (2013)

High Isoniazid Resistance Rates in Rifampicin Susceptible Mycobacterium tuberculosis Pulmonary Isolates from Pakistan
por: Fasih, Naima, et al.
Publicado: (2012)

Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China
por: Huo, Fengmin, et al.
Publicado: (2019)

Methionine Antagonizes para-Aminosalicylic Acid Activity via Affecting Folate Precursor Biosynthesis in Mycobacterium tuberculosis
por: Howe, Michael D., et al.
Publicado: (2018)

Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis
por: Chen, Suting, et al.
Publicado: (2017)

Para-Aminosalicylic Acid: Pas
Publicado: (1950)

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China
por: Wang, Chenqian, et al.
Publicado: (2022)

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes
por: Wang, Wei, et al.
Publicado: (2022)

Clinical Study of the Use of Para-Aminosalicylic Acid in the Treatment of Pulmonary Tuberculosis
por: Donaldson, Rose I. L.
Publicado: (1949)

Relapse Versus Reinfection of Recurrent Tuberculosis Patients in a National Tuberculosis Specialized Hospital in Beijing, China
por: Zong, Zhaojing, et al.
Publicado: (2018)

Doubled Nontuberculous Mycobacteria Isolation as a Consequence of Changes in the Diagnosis Algorithm
por: Chen, Suting, et al.
Publicado: (2022)

Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug resistant Mycobacterium tuberculosis
por: Harrison, Gregory A., et al.
Publicado: (2023)

Discovery of Novel Enhancers of Isoniazid Toxicity in Mycobacterium tuberculosis
por: Lentz, Fabian, et al.
Publicado: (2018)

A Rapid Assessing Method of Drug Susceptibility Using Flow Cytometry for Mycobacterium tuberculosis Isolates Resistant to Isoniazid, Rifampin, and Ethambutol
por: Lee, Sun-Kyoung, et al.
Publicado: (2022)

Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
por: Huo, Fengmin, et al.
Publicado: (2020)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

Pattern of InhA and KatG mutations in isoniazid monoresistant Mycobacterium tuberculosis isolates
por: Charan, Ashok Singh, et al.
Publicado: (2020)

Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates
por: Muthaiah, Muthuraj, et al.
Publicado: (2017)

Association Between the Phenotype and Genotype of Isoniazid Resistance Among Mycobacterium tuberculosis Isolates in Thailand
por: Charoenpak, Ratchanu, et al.
Publicado: (2020)

Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa
por: Traoré, Afsatou Ndama, et al.
Publicado: (2023)

Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families
por: Kasule, George W., et al.
Publicado: (2016)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis
por: Gagneux, Sebastien, et al.
Publicado: (2006)

Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis
por: Machado, Diana, et al.
Publicado: (2012)

Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis
por: Lee, Jong-Hee, et al.
Publicado: (2012)

Isoniazid MIC and KatG Gene Mutations among Mycobacterium tuberculosis Isolates in Northwest of Iran
por: Moaddab, Seed Reza, et al.
Publicado: (2011)

Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance
por: Satta, Giovanni, et al.
Publicado: (2016)

Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda
por: Kigozi, Edgar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_317gs4fccugfihrjb8carilli9